Issue Date: May 27, 2013
Europeans Seek Competitive Advantage From Continuous Processing
The spate of drug patent expirations known as the patent cliff is sharpening minds. Pharmaceutical companies have been looking under every rock to save money, and one idea they have found is continuous chemical manufacturing. Momentum to develop continuous processes is especially building in Europe, where firms hope that by working together and with academia they can get a jump on the competition.
Delegates at a meeting held recently at AstraZeneca’s R&D center . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society